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Abstract
Objective—To estimate fatal and nonfatal opioid overdose events in pregnant and postpartum 
women in Massachusetts, comparing rates in individuals receiving and not receiving 
pharmacotherapy for opioid use disorder (OUD).
Methods—We conducted a population-based retrospective cohort study using linked 
administrative and vital statistics databases in Massachusetts to identify women with evidence of 
OUD who delivered a live birth in 2012–2014. We described maternal sociodemographic, medical, 
and substance use characteristics, computed rates of opioid overdose events in the year before and 
after delivery, and compared overdose rates by receipt of pharmacotherapy with methadone or 
buprenorphine in the prenatal and postpartum periods.
Results—Among 177,876 unique deliveries, 4,154 (2.3%) were to women with evidence of 
OUD in the year prior to delivery, who experienced 242 total opioid-related overdose events (231 
non-fatal, 11 fatal) in the year before or after delivery. The overall overdose rate was 8.0/100,000 
person-days. Overdose were lowest in the third trimester (3.3/100,000 person-days in third 
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trimester) then increased in the postpartum period, with the highest overdose rate 7–12 months 
after delivery (12.3/100,000 person-days). Overall, 64.3% of women with evidence of OUD in the 
year prior to delivery received any pharmacotherapy in the year prior to delivery. Women receiving 
pharmacotherapy had reduced overdose rates in the early postpartum period.
Conclusion—Pregnant women in Massachusetts have high rates of OUD. The year after delivery 
is a vulnerable period for women with OUD. Additional longitudinal supports and interventions 
tailored to women in the first year postpartum are needed to prevent and reduce overdose events.
Introduction
Opioid-related overdose deaths have more than quadrupled over the past fifteen years, 
representing a public health emergency.1–3 The rates of heroin use and prescription opioid-
related overdose deaths are rising faster in women than in men, particularly women of 
reproductive age.4–6 Multiple states have identified opioid-related overdoses as a major 
contributor to pregnancy-associated deaths. Among all pregnancy associated deaths, 11–
20% were due to opioid-overdose.7–9
Recent estimates of opioid use disorder (OUD) range from 0.4% to 0.8% during pregnancy 
to 2% among women of reproductive age.10,11 Pregnancy is often seen as a motivating time 
for women to reduce substance use and begin substance use treatment.12,13 For pregnant 
women with OUD, the standard of care is behavioral therapy and pharmacotherapy with 
methadone or buprenorphine, which improves obstetrical, infant, and substance use 
outcomes.14–17 Although many pregnant women with OUD initiate pharmacotherapy, 
disengagement from pharmacotherapy occurs at high rates, increasing the risk of relapse.
18,19
 Little is known about the timing of opioid-related overdoses and the relationship of 
pharmacotherapy to relapse during the prenatal and postpartum period.
The purpose of this study is to explore the impact of overdose events in pregnant and 
postpartum women in Massachusetts using a linked-statewide population-level dataset. Our 
study aims to: (1) Investigate trends in overdose events in women with OUD in the year 
prior to and after delivery; and (2) Compare overdose rates by receipt of pharmacotherapy. 
We hypothesized that the rate of overdose events decreased as pregnancy progressed but 
increased after delivery and overdose rates were lower in women receiving 
pharmacotherapy.
Materials and Methods
We conducted a population-based retrospective cohort study using a statewide linked 
database created in response to a mandate from the Massachusetts legislature and overseen 
by the Massachusetts Department of Public Health (MDPH).20 Chapter 55 of the Acts of 
2015 mandated that the MDPH analyze data from several Massachusetts government 
agencies to identify and report on fatal and non-fatal opioid overdose trends.20 Linkage 
across data sets at the individual level allowed for a deeper understanding of the 
circumstances that influence opioid overdoses. The following data sources for calendar years 
2011–2015 were linked at the individual level to allow for a deeper understanding of the 
circumstances that influence overdose: the Massachusetts All Payer Claims Database, 
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inpatient hospitalization, emergency department visits, and outpatient observations from the 
Center for Health Information and Analysis discharge records, vital records birth and death 
certificates, Bureau of Substance Addiction Services substance use disorder treatment data, 
the Massachusetts Prescription Drug Monitoring Program, and Massachusetts Ambulance 
Trip Record Information System, among others. A full description of the datasets linked, 
data structure, and linkage rates across datasets has been described previously by the 
MDPH.21,22 For the All Payer Claims Database, the core dataset for which all other data 
were linked to, medical claims from insurers are normalized to ensure completeness and 
validity and enable accurate cross-payer and cross-provider research and analyses.23 In 
general, for each independent dataset linked to the Chapter 55 dataset, data collection, 
maintenance, and internal validation is performed by the MA public health agency 
responsible for that database.
We included all Massachusetts female residents who delivered a live birth (with a gestational 
age ≥ 20 weeks), identified via linkage with a birth certificate. Birth certificate linkage rates 
for our study period was 91.7%. Our study cohort was limited to deliveries that occurred 
between 01/01/12 and 09/30/14, to allow for a full year of available data before and after 
each delivery. The study population includes both singleton and multiple births, as well as 
multiple deliveries to the same woman in the study period. Appendix 1, available online at 
http://links.lww.com/xxx, shows schematically how the study population was defined.
To focus on women who would most benefit from pharmacotherapy during pregnancy and 
the postpartum period, we further restricted the cohort to individuals with evidence of OUD 
in the year prior to delivery. Evidence of OUD was defined as the presence of any of the 
following criteria in linked records: (1) International Classification of Disease, Ninth 
Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, Clinical Modification 
(ICD-10-CM) codes related to OUD in hospital discharge or claims records24; (2) an opioid 
overdose event, as further defined below; (3) enrollment in a state-funded treatment program 
for an “opioid problem”; (4) claims for methadone maintenance treatment (including only 
Healthcare Common Procedure Coding System code H0020 (methadone administration by a 
licensed program) to exclude claims of methadone prescribed for pain); (5) receipt of 
methadone from a state-funded treatment program; (6) filled prescription for buprenorphine 
or combined buprenorphine and naloxone; or (7) infant diagnosis of neonatal abstinence 
syndrome (NAS). Diagnoses of NAS were identified via linked infant claims records. For 
mothers identified solely by a diagnosis of NAS, infants born ≤ 34 weeks gestational age 
were excluded to prevent misclassification of iatrogenic cases of NAS. Appendix 2, 
available online at http://links.lww.com/xxx, specifies the ICD codes used for case 
identification, and Appendix 3, available online at http://links.lww.com/xxx, shows the 
proportion of deliveries with evidence of OUD identified from each data source and 
proportion of deliveries identified uniquely by only a single data source.
Our primary outcome of interest was fatal or nonfatal opioid-related overdose events. 
Opioid-related overdose events were defined as having any of the following: (1) A death 
certificate indicating opioid overdose as cause of death. (2) An admission to an inpatient 
unit, observation unit, or an emergency department encounter with an indication of opioid 
overdose based on ICD-9-CM diagnosis codes for opioid poisoning (Appendix 2, http://
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links.lww.com/xxx); or (3) An ambulance incident with an indication of opioid overdose 
based on an algorithm created and refined by MPDH in collaboration with the Centers for 
Disease Control and Prevention (data available from January 1, 2013–December 31, 2015); 
To assess for validity across multiple datasets, the number of overdose events reported after 
a confirmed death was assessed and found to be zero (Appendix 4, available online at http://
links.lww.com/xxx). Additionally, ambulance and hospital encounters recorded on the same 
calendar day were assumed to describe a single overdose event (Appendix 4, http://
links.lww.com/xxx). Because our identification of pregnancy relied on the delivery of a live 
birth, women who may have had a fatal overdose while pregnant were not able to be 
identified.
We compared the characteristics of our cohort with evidence of overdose events, with those 
who had evidence of OUD in the year prior to delivery but without overdose, and all other 
women who delivered a live birth using descriptive statistics and chi-square tests. Maternal 
age in the year of delivery, race and ethnicity, marital status, employment status, highest 
educational level, and the adequacy of prenatal care utilization index25 were extracted from 
birth certificate data. Evidence of homelessness was defined as homelessness at any time 
during the study period from 2011–2015, identified from predictive modeling in the overall 
linked dataset.24 Finally, evidence of anxiety and depression were recorded from claims data 
and was defined as any claim during the entire study period from 2011–2015. All analyses 
were performed in SAS Enterprise.
The year prior to and post-delivery was divided into eight time periods of interest using date 
of delivery and gestational age recorded on the birth certificate. The year prior to delivery 
was divided into four periods, (1) preconception, representing the time from one year prior 
to due date to conception, (2) first trimester, (3) second trimester, and (4) third trimester, 
which varied in length based on gestational age (Appendix 5, available online at http://
links.lww.com/xxx). The year after delivery was equally divided into four three-month 
intervals, (5) 0–3 months, (6) 4–6 months, (7) 7–9 months, and (8) 10–12 months. The 
number of days each woman spent in each time period was totaled to calculate the number 
of person-days. For each time period the total numbers of overdose events and person-days 
under observation were calculated for the cohort and used to estimate a set of overall 
overdose rates. Women were not censored upon experiencing a non-fatal overdose event, but 
were censored at the time of death. Given overdose was a rare event, 95% confidence 
intervals were computed using the Poisson distribution.
Monthly receipt of pharmacotherapy was determined based on evidence of: (1) A claim for 
methadone maintenance (as described above); (2) enrollment in a state-funded opioid 
treatment program receiving methadone; or (3) a filled prescription containing 
buprenorphine. Because use of naltrexone is not standard practice during pregnancy, this 
medication was not included. Overdose events were then classified into two groups: 
occurring in a month where the woman had any evidence of receipt of pharmacotherapy 
(“overdose events on pharmacotherapy”), or occurring in a month where a woman had no 
evidence of receipt of pharmacotherapy (“overdose events without pharmacotherapy”). To 
determine the total number of person-days that contributed to the denominator for the rate in 
each group, we had to estimate the number of days on which an individual had received 
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pharmacotherapy from the treatment data that was available on a monthly basis. Due to 
privacy limitations on the dataset, we could not identify the specific day in a calendar month 
that the delivery took place. In order to account for this limitation, in the month of delivery 
individuals were assigned an equal number of person-days to the period just prior to and 
after pregnancy. For example, if a woman had received treatment during the month of 
delivery, she would contribute 15 person-days to the denominator of the third trimester “on 
pharmacotherapy” period and 15 person-days to the denominator of the 0–3 months 
postpartum “on pharmacotherapy” period.” From here, monthly treatment data was then 
mapped onto the eight time periods described above. Appendix 5 (http://links.lww.com/xxx) 
shows the amount of time each delivery contributed to each time period based on gestational 
age.
First, to examine the effect of including multiple deliveries for the same woman, we 
compared overdose rates for the entire cohort with rates including only a woman’s first 
delivery during the study period. Second, we evaluated the number of women who had an 
overdose event in the year after delivery, but had no evidence of opioid use disorder in the 
year prior to delivery. We then compared the rates when including all women with evidence 
of opioid use disorder during the year prior to or post-delivery with the rates from the 
original cohort.
This work was mandated by law, and conducted by a public health authority. The MDPH 
was not engaged in human subjects research, and as a result, it was determined that no 
Institutional Review Board (IRB) was required. The Boston University IRB additionally 
deemed this study non-human subjects research.
Results
A total of 169,206 Massachusetts female residents who delivered a live birth were identified 
during the study period, experiencing 177,876 unique deliveries, representing 183,466 
unique births (Figure 1). There were 6,861 (3.9%) deliveries to women with evidence of 
opioid use disorder documented anytime from 2011–2015 and 5,016 (2.8%) deliveries to 
women with evidence of opioid use disorder in the year prior to or post-delivery. In our 
cohort, there were 4,154 (2.3%) deliveries to women with evidence of opioid use disorder in 
the year prior to delivery. Overall, there was a total of 242 overdose events (231 non-fatal 
and 11 fatal) occurring among 184 deliveries in our cohort. In 25% of deliveries, a woman 
experienced more than a single overdose event within the year prior to or after delivery, with 
the number of overdose events experienced per individual ranging from 1 to 4.
The characteristics of the sample population are described in Table 1. Compared with 
women with evidence of opioid use disorder who had no overdose events and all women 
who delivered a live birth, women with an overdose event were more likely to be younger, 
single, unemployed, lacking a high school degree, receiving public insurance, and receiving 
inadequate prenatal care. Women with an overdose event had significantly higher co-
occurring homelessness, and psychiatric conditions. Seventy-nine percent of women with an 
overdose event had some evidence of homelessness compared with 34% of women with 
opioid use disorder but no overdose and 2% of women who delivered a live birth without 
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opioid use disorder (p <0.001). Women with an overdose event were significantly more 
likely to have evidence of anxiety (82% with overdose v. 60% with opioid use disorder but 
no overdose v. 18% of deliveries without opioid use disorder (p <0.001)) and depression 
(85% with overdose v. 61% with opioid use disorder but no overdose v. 19% of deliveries 
without opioid use disorder (p <0.001)). Overall, 64.3% of deliveries to women with 
evidence of opioid use disorder received any pharmacotherapy in the year prior to delivery.
The overall rate of opioid-related overdose events in the cohort was 8.0 per 100,000 person 
days. Overdose events decreased as women progressed throughout pregnancy and were 
lowest in the third trimester at 3.3 per 100,000 person days (95% CI 1.6–6.1 per 100,000 
person days, then increased in the postpartum period (Table 2). The highest risk of overdose 
occurred 7–12 months after delivery, when the rate was 12.3 per 100,000 person days (95% 
CI 9.9–15.0 per 100,000 person days). When comparing opioid overdose rates by receipt of 
pharmacotherapy, rates on treatment are lower than rates off treatment in every time-period 
except for the third trimester, when the number of events was low in both groups, but only 
reached statistical significance in the 4–6 months post delivery (1.3 per 100,000 person days 
on pharmacotherapy (95% CI 0.16–4.74) v. 10.7 per 100,000 person days for those not on 
pharmacotherapy (95% CI 6.84–15.88) (Table 2 and Figure 2). At 7–12 months postpartum, 
the opioid overdose rates increased for both women receiving pharmacotherapy and those 
not receiving treatment (Figure 2). The number of overdose events and number of person-
days in each time period is shown in Appendix 6, available online at http://links.lww.com/
xxx.
We identified 6.6% of the deliveries in the cohort as second or third deliveries to the same 
woman. Restricting our cohort to just a single delivery per woman did not significantly 
change the opioid overdose rates (data not shown). Finally, there were 78 women, each with 
a single delivery, who had 93 opioid-related overdose events in the year after delivery, but 
had no evidence of OUD in the year prior to delivery. Deliveries among these women (no 
OUD prenatally, overdose postnatally) were significantly more likely to occur in women 
who: were under 25 years, were non-White, had paid employment, received adequate 
prenatal care, had private insurance, had evidence of homelessness, and did not have a 
diagnosis of anxiety or depression compared with women with an overdose who had 
evidence of OUD in the year prior to pregnancy (p-value for all analyses < 0.05).
Discussion
Using a unique population-based linked-dataset to identify women with OUD, we 
determined the timing and rates of fatal and non-fatal overdose events among women who 
delivered a live birth in Massachusetts. Overdose events were lowest in the third trimester 
but increased after delivery, with the highest rates 7–12 months postpartum. Overall, 
overdose rates among women receiving pharmacotherapy in the month of overdose were 
statistically significantly lower compared with those not receiving pharmacotherapy. 
Additionally, pregnant women in MA with OUD had significantly higher rates of 
homelessness and psychiatric conditions compared to all other pregnant women in MA.
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Our study identified the first year postpartum as a period where mothers are at higher risk of 
overdose events. We hypothesize several explanations. First, compared with the prenatal 
period when resources are prioritized for pregnant women with OUD, the postpartum period 
can be difficult as fewer special services continue after delivery.26,27 Second, the shame and 
stigma mothers experience watching their infant’s symptoms of withdrawal from in-utero 
opioid exposure can make the immediate post-partum period particularly challenging.28,29 
Third, postpartum hormonal changes can make it difficult to determine optimum 
pharmacotherapy dose for maintaining recovery.30 Fourth, the high rates of co-occurring 
depression, anxiety, and homelessness may put women at higher risk of postpartum 
depression, which has been shown to impact relapse.31
The second six months after delivery were a particularly vulnerable period. Discontinuing 
pharmacotherapy in the postpartum period may play a role in the higher overdose rates, as 
retention is associated with significant reductions in overdose mortality in all persons with 
OUD32. Few studies have previously reported on post-partum pharmacotherapy 
discontinuation, yet in a single-site cohort of methadone-maintained mothers with OUD, 
Wilder and colleagues found a 56% discontinuation rate by six months post-partum.18 In our 
cohort, relapse may have occurred significantly earlier than an overdose event that requires 
medical attention, but the presence of more potent synthetic opioids like illicitly 
manufactured fentanyl in the heroin supply increases the risk of overdose during a first 
relapse.33
Finally, we identified over 2% of women had evidence of OUD in the year prior to delivery, 
higher than previously published national representative samples of OUD in pregnancy of 
0.4–0.8%, although definitions of OUD differ across the studies.10,11 Our dataset allowed 
for a broader and more contemporary examination of OUD throughout pregnancy, relying on 
multiple different data sources and touchpoints with the health care system prior to a 
woman’s delivery for a more inclusive understanding of the burden of OUD in pregnant 
women in Massachusetts, a state significantly impacted by the opioid epidemic.24
Our study is subject to several limitations. First, we identified our cohort of women based on 
the linkage with a newborn’s birth certificate, and were unable to identify pregnant women 
who experienced a fatal overdose during pregnancy, died from another cause, or did not 
deliver a live birth. Therefore, our study may underestimate the burden in the prenatal 
period. Second, as treatment data were only available on a monthly basis, we could not 
determine if an individual was actively receiving treatment when overdose occurred. It is 
possible that some people discontinued treatment prior to the overdose event or started after, 
thus resulting in a misclassification as receiving pharmacotherapy, biasing observed 
overdose event rates higher while on treatment. Third, although we estimated the number of 
person-days just before and after delivery, we do not expect this estimation biased our 
findings towards either the treated or untreated group. Fourth, these analyses did not adjust 
for potential confounding factors that may be associated with both receipt of treatment and 
overdose. Fifth, ambulance trip data was not available until 2013, potentially impacting our 
ability to identify some overdose events not ending in a transport to an emergency 
department. Finally, we relied on the use of administrative and billing data, which is subject 
to reporting errors and underreporting.
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Despite these limitations, this study shows that opioid overdose events are lowest in the third 
trimester but increase in the year after delivery, with 7–12 months postpartum a particularly 
vulnerable time for women with OUD using a large population-based analysis in 
Massachusetts. Further research is needed to explore additional predictors of overdose 
events, specifically in the postpartum period including housing stability, comorbid 
psychiatric conditions and child protective services involvement. Targeted interventions that 
promote non-judgmental, universal screening for OUD during pregnancy, longitudinal care 
of women throughout pregnancy and their families into the postpartum period which 
emphasizes pharmacotherapy, mental health treatment, supportive housing, overdose 
education, and naloxone access to support long-term recovery and safety should be 
implemented.
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Figure 1. 
Cascade of deliveries by Massachusetts residents, January 2012 to September 2014.
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Figure 2. 
Opioid overdose rates among pregnant and parenting women with evidence of opioid use 
disorder in year prior to delivery (n=4,154). All overdose events (A), stratified by receipt of 
pharmacotherapy during month of overdose event (B). Error bars represents 95% CIs. First 
trimester defined at 0–12 weeks of gestation, second trimester defined as 13–28 weeks of 
gestation, and third trimester defined as ≥29 weeks of gestation.
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